SCHEMBL3473025

SCHEMBL3473025

CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(=O)Nc4ccccn4)nn3-c3ccccc3Cl)s2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.73
NR1H2 P55055 7/20 0.73
NR1H3 Q13133 7/20 0.73
RIPK1 Q13546 1/20 0.47
CNR1 P21554 1/20 0.44
PRF1 P14222 1/20 0.40
CNR2 P34972 1/20 0.38
TSHR P16473 2/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
GRM5 P41594 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SLC16A3 O15427 1/20 0.38
SLC16A1 P53985 1/20 0.38
MCTS1 Q9ULC4 1/20 0.38
GAA P10253 1/20 0.37
FLT3 P36888 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14623269 0.88 RXRA (0.80) RXRANR1H2NR1H3CNR1SLC16A3
SCHEMBL15641686 0.88 RXRA (0.70) RXRANR1H2NR1H3L3MBTL1NPC1
SCHEMBL3472056 0.88 RXRA (0.72) RXRANR1H2NR1H3CNR1GRM5
SCHEMBL3471545 0.88 RXRA (0.74) RXRANR1H2NR1H3CNR1CNR2
SCHEMBL3472823 0.87 RXRA (0.73) RXRANR1H2NR1H3CNR1GRM5
SCHEMBL3474515 0.86 RXRA (0.67) RXRANR1H2NR1H3CNR1TSHR
SCHEMBL3474015 0.86 RXRA (0.69) RXRANR1H2NR1H3CNR1HTT
SCHEMBL3472718 0.86 RXRA (0.82) RXRANR1H2NR1H3CNR1SLC16A3
SCHEMBL3472973 0.86 NR1H2 (0.77) RXRANR1H2NR1H3CNR1SLC16A3
SCHEMBL3471521 0.85 RXRA (0.71) RXRANR1H2NR1H3CNR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.